Decision Patent Owner's Motion to Expunge Confidential Information | Apr 28, 2021 | PAPER | BOARD |
Patent Owner's Motion to Expunge | Feb 24, 2021 | PAPER | PATENT OWNER |
TERMINATION
Due to Settlement on Remand
37 C.F.R. ¿¿ 42.74 | Jan 8, 2021 | PAPER | BOARD |
Joint Motion to Terminate Proceeding and Request to Treat Settlement Agreement as Business Confidential Information and be Kept Separate | Nov 12, 2020 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List as of November 12, 2020 | Nov 12, 2020 | PAPER | PATENT OWNER |
Confidential Settlement and License Agreement | Nov 12, 2020 | EXHIBIT | PATENT OWNER |
Petitioner Argentum's Sur-Reply ISO Opposition to Motion to Terminate | Aug 11, 2020 | PAPER | PETITIONER |
EXPUNGED | Aug 4, 2020 | PAPER | BOARD |
Ex. 3003 | Aug 4, 2020 | EXHIBIT | BOARD |
Order Granting Sur-Reply for Motion to Terminate | Aug 4, 2020 | PAPER | BOARD |
Reply Brief In Support Of Joint Motion To Terminate Proceeding And Request To Treat Settlement Agreement As Business Confidential Information And Be Kept Separate | Aug 2, 2020 | PAPER | PATENT OWNER |
Petitioner Argentum's Opposition to Joint Motion to Terminate Proceeding | Jul 27, 2020 | PAPER | PETITIONER |
Conduct of the Proceeding | Jun 22, 2020 | PAPER | BOARD |
Exhibit 3002 | Jun 22, 2020 | EXHIBIT | BOARD |
Joint Motion to Terminate Proceeding and Request to Treat Settlement Agreement as Business Confidential Information and Be Kept Separate | May 13, 2020 | PAPER | PATENT OWNER |
Confidential Settlement and License Agreement | May 13, 2020 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 29, 2019 | PAPER | BOARD |
Order Lifting Reissue Stay | Mar 29, 2019 | PAPER | BOARD |
Patent Owner's Seventh Updated Mandatory Notices | Jan 16, 2019 | PAPER | PATENT OWNER |
Patent Owner¿¿¿s Unopposed Motion for
Pro Hac Vice Admission of Joseph T. Jaros
37 C.F.R. sec. 42.10 | Dec 21, 2018 | PAPER | BOARD |
Patent Owner¿¿¿s Unopposed Motion for
Pro Hac Vice Admission of William A. Rakoczy
37 C.F.R. sec. 42.10 | Dec 21, 2018 | PAPER | BOARD |
Conduct of the Proceeding
37 C.F.R. sec. 42.5 | Dec 21, 2018 | PAPER | BOARD |
Notification of Receipt of POP Request | Dec 10, 2018 | PAPER | BOARD |
Ex. 3001 | Dec 10, 2018 | EXHIBIT | BOARD |
Patent Owner's Sixth Updated Mandatory Notices | Dec 6, 2018 | PAPER | PATENT OWNER |
DECLARATION OF WILLIAM A RAKOCZY IN SUPPORT OF MOTION FOR PRO HAC ADMISSION | Sep 25, 2018 | PAPER | PETITIONER |
ACRUX'S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF
WILLIAM A. RAKOCZY | Sep 25, 2018 | PAPER | PETITIONER |
ACRUX'S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF JOSEPH T. JAROS | Sep 25, 2018 | PAPER | PETITIONER |
DECLARATION OF JOSEPH T. JAROS IN SUPPORT OF MOTION FOR PRO HAC ADMISSION | Sep 25, 2018 | PAPER | PETITIONER |
DECLARATION OF JOSEPH T JAROS IN SUPPORT OF MOTION FOR PRO HAC ADMISSION | Sep 25, 2018 | PAPER | PETITIONER |
Decision - 37 C.F.R. 42.10 | Sep 19, 2018 | PAPER | BOARD |
ACRUX'S UPDATED MANDATORY NOTICES | Sep 18, 2018 | PAPER | PETITIONER |
ACRUX'S REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY PURSUANT TO 37 C.F.R. ¿¿ 42.10(b) | Aug 28, 2018 | PAPER | PETITIONER |
ACRUX'S UNOPPOSED MOTION TO WITHDRAW COUNSEL AND SUBSTITUTE NEW COUNSEL | Aug 28, 2018 | PAPER | PETITIONER |
Patent Owner's Fifth Updated Mandatory Notices | Aug 14, 2018 | PAPER | PATENT OWNER |
Patent Owner's Notice of Appeal | Aug 7, 2018 | PAPER | PATENT OWNER |
Patent Owner's Request for Rehearing Under 37 C.F.R. 42.71(d), and for an Expanded Panel | Jul 27, 2018 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Jul 27, 2018 | PAPER | PATENT OWNER |
Kaken Exhibit 2203 | Jul 27, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner's Motion to Preserve the Record | Jul 23, 2018 | PAPER | PATENT OWNER |
ERRATA | Jun 11, 2018 | PAPER | BOARD |
Decision Motions to Seal | Jun 6, 2018 | PAPER | BOARD |
Final Written Decision | Jun 6, 2018 | PAPER | BOARD |
Decision Motions to Strike and to Exclude | Jun 6, 2018 | PAPER | BOARD |
Hearing Transcript | Apr 11, 2018 | PAPER | BOARD |
Trial Order | Jan 12, 2018 | PAPER | BOARD |
PETITIONERS¿¿¿ MOTION TO SEAL | Jan 12, 2018 | PAPER | PETITIONER |
PUBLIC VERSION - PETITIONERS¿¿¿ REPLY IN SUPPORT OF THEIR MOTION TO EXCLUDE UNDER 37 C.F.R. ¿¿ 42.64(c) | Jan 12, 2018 | PAPER | PETITIONER |
EXPUNGED | Jan 12, 2018 | PAPER | PETITIONER |
Patent Owner's Reply in Support of its Motion to Exclude | Jan 12, 2018 | PAPER | PATENT OWNER |
PETITIONERS¿¿¿ MOTION TO SEAL | Jan 5, 2018 | PAPER | PETITIONER |
PETITIONERS¿¿¿ OPPOSITION TO PATENT OWNER¿¿¿S MOTION TO EXCLUDE UNDER 37 C.F.R. ¿¿ 42.64(c) | Jan 5, 2018 | PAPER | PETITIONER |
EXPUNGED | Jan 5, 2018 | PAPER | PETITIONER |
PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF DR. KENNETH A. WALTERS | Jan 5, 2018 | PAPER | PETITIONER |
PUBLIC VERSION - PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION
FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF JOHN C. STAINES, JR. | Jan 5, 2018 | PAPER | PETITIONER |
PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION FOR OBSERVATIONS ON THE CROSS-EXAMINATION OF DR. JEFFREY M. WEINBERG | Jan 5, 2018 | PAPER | PETITIONER |
Exhibit 1513(a) - Tadashi Arika et al., Nishi Nihon Journal of Dermatology, 52 (3): 545-549 (1990) | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1522(a) - Theodore Rosen et al., Seminars in Cutaneous Medicine and Surgery: Onychomycosis- Diagnosis, Treatment, and Prevention Strategies (Supp. 3), 35 (3S): S51- S55 (2016) | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1543(a) - ¿¿¿Is Walgreens Valeant¿¿¿s New Philidor?¿¿¿ D. A. Hussar, The Pharmacist Activist, vol. 11, no. 2 (February 2016) | Jan 5, 2018 | EXHIBIT | PETITIONER |
PETITIONERS UPDATED EXHIBIT LIST - (as of January 5, 2018) | Jan 5, 2018 | PAPER | PETITIONER |
Prosecution History of U.S. Pat. App. No. 15,405,171 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Declaration of Aydin H. Harston in Support of Supplemental Evidence Served May 30, 2017, with attached exhibits | Jan 5, 2018 | EXHIBIT | PETITIONER |
Declaration of Caitlin M. Wilmot in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Declaration of Aydin H. Harston in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Declaration of John C. Staines, Jr. in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Declaration of Lisa N. Phillips in Support of Petitioners¿¿¿ Response to Patent Owner¿¿¿s Objections to Evidence Served November 22, 2017 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1535(a) - "Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?¿¿¿ P.M. Danzon, International Journal of the Economics of Business, 22(2):245-261 (2015). | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1547(a) - Citron Research, Valeant: Could this be the Pharmaceutical Enron?, For the Rest of the Story, Click Here | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1554(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2016 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1603(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2013 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1619(a) - ¿¿¿Physicians-Pharmaceutical Sales Representatives interactions and Conflict of Interest: Challenges and Solutions,¿¿¿ A.R. Patwardhan, The Journal of Health Care Organization, Provision, and Financing, 53:1-5 (2016) | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1626(a) - ¿¿¿Copay Programs¿¿¿ Increased Value to Manufacturers is Matched by Rising Criticism,¿¿¿ S. Shelly, Pharmaceutical Commerce, 9(1): 1-32 (January 15, 2014) | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1544(a) - ¿¿¿The King¿¿¿s Gambit: Valeant¿¿¿s Big Secret,¿¿¿ R. Boyd, Southern Investigative Reporting Foundation, October 19, 2015 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1553(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1588(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended June 30, 2017 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1604(a) - Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2012 | Jan 5, 2018 | EXHIBIT | PETITIONER |
Exhibit 1623(a) - ¿¿¿An Exploratory Study to Improve Sales Operations When Selling Multiple Prescription Drugs,¿¿¿ J.C. Yi, M. Zhou, T. Park, Journal of Supply Chain and Operations Management, 9:43-53 (February 2011) | Jan 5, 2018 | EXHIBIT | PETITIONER |
Patent Owner's Opposition to Petitioners' Motion to Exclude Evidence Submitted by Patent Owner under 37 C.F.R. 42.64(C) (REDACTED VERSION) | Jan 5, 2018 | PAPER | PATENT OWNER |
Kaken Exhibit 2111 | Jan 5, 2018 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 5, 2018 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Jan 5, 2018 | PAPER | PATENT OWNER |
Patent Owner's Motion to Seal Patent Owner's Opposition to Petitioners' Motion to Exclude Evidence | Jan 5, 2018 | PAPER | PATENT OWNER |
Kaken Exhibit 2112 | Jan 5, 2018 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2113 | Jan 5, 2018 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2202 | Jan 5, 2018 | EXHIBIT | PATENT OWNER |
PETITIONERS¿¿¿ MOTION TO SEAL | Dec 22, 2017 | PAPER | PETITIONER |
EXPUNGED | Dec 22, 2017 | PAPER | PETITIONER |
PUBLIC VERSION - PETITIONERS¿¿¿ MOTION TO EXCLUDE EVIDENCE SUBMITTED BY PATENT OWNER UNDER 37 C.F.R. ¿¿ 42.64(c) | Dec 22, 2017 | PAPER | PETITIONER |
E-mail string, initiated on August 10, 2017 | Dec 22, 2017 | EXHIBIT | PETITIONER |
PETITIONER'S UPDATED EXHIBIT LIST | Dec 22, 2017 | PAPER | PETITIONER |
PETITIONERS¿¿¿ REQUEST FOR ORAL ARGUMENT PURSUANT TO 37 C.F.R. ¿¿ 42.70(a) | Dec 22, 2017 | PAPER | PETITIONER |
Patent Owner's Motion for Observations on the Cross-Examination of John C. Staines, Jr. | Dec 22, 2017 | PAPER | PATENT OWNER |
Patent Owner's Motion for Observations on the Cross-Examination of Jeffrey M. Weinberg, M.D. | Dec 22, 2017 | PAPER | PATENT OWNER |
Patent Owner's Motion for Observations on the Cross-Examination of Kenneth A. Walters | Dec 22, 2017 | PAPER | PATENT OWNER |
Patent Owner's Motion to Exclude Under 37 C.F.R. 42.64(C) | Dec 22, 2017 | PAPER | PATENT OWNER |
Patent Owner's Motion to Seal Exhibit 2116 | Dec 22, 2017 | PAPER | PATENT OWNER |
Kaken Exhibit 2116 (REDACTED VERSION) | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Dec 22, 2017 | PAPER | PATENT OWNER |
EXPUNGED | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2117 | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2118 | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2200 | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2201 | Dec 22, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Request for Oral Hearing | Dec 22, 2017 | PAPER | PATENT OWNER |
PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED DURING THE DEPOSITIONS OF KENNETH A. WALTERS, Ph.D. AND JEFFREY M. WEINBERG, M.D. PURSUANT TO 37 C.F.R. ¿¿ 42.64 | Dec 13, 2017 | PAPER | PETITIONER |
EXPUNGED | Dec 6, 2017 | PAPER | PETITIONER |
PETITIONERS¿¿¿ RESPONSE TO PATENT OWNER¿¿¿S MOTION TO STRIKE | Dec 6, 2017 | PAPER | PETITIONER |
PETITIONER¿¿¿S UPDATED NOTICE OF COUNSEL UNDER 37 C.F.R. ¿¿ 42.8 | Nov 27, 2017 | PAPER | PETITIONER |
Patent Owner's Motion to Strike | Nov 27, 2017 | PAPER | PATENT OWNER |
Order Conduct of the Proceeding | Nov 21, 2017 | PAPER | BOARD |
Notice of Deposition of Kenneth A. Walters, Ph.D. | Nov 21, 2017 | PAPER | PATENT OWNER |
Notice of Deposition of John C. Staines, Jr. | Nov 20, 2017 | PAPER | PATENT OWNER |
Notice of Deposition of Jeffrey M. Weinberg, M.D. | Nov 20, 2017 | PAPER | PATENT OWNER |
COPY of Order Joining IPR2017-01429 with IPR2017-00190 | Nov 13, 2017 | PAPER | BOARD |
Patent Owner's Objections to Evidence Submitted with Petitioner's Reply | Nov 8, 2017 | PAPER | PATENT OWNER |
PETITIONER¿¿¿S MOTION TO SEAL | Nov 1, 2017 | PAPER | PETITIONER |
Petitioners Reply to Patent Owners Response | Nov 1, 2017 | PAPER | PETITIONER |
Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy | Nov 1, 2017 | EXHIBIT | PETITIONER |
Onychomycosis | Nov 1, 2017 | EXHIBIT | PETITIONER |
Trends in the management of cutaneous fungal infections | Nov 1, 2017 | EXHIBIT | PETITIONER |
Guidelines for treatment of onychomycosis | Nov 1, 2017 | EXHIBIT | PETITIONER |
Meeting Minutes for IND 77732, Division of Dermatology and Dental Products: Office of Drug Evaluation III | Nov 1, 2017 | EXHIBIT | PETITIONER |
U.S. Pat. No. 5,962,476 to Naito et al | Nov 1, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 1, 2017 | EXHIBIT | PETITIONER |
PUBLIC VERSION Deposition Transcript of Dr. Yoshiyuki Tatsumi | Nov 1, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 1, 2017 | EXHIBIT | PETITIONER |
PUBLIC VERSION Deposition Transcript of Vincent A. Thomas | Nov 1, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Dr. Boni E. Elewski | Nov 1, 2017 | EXHIBIT | PETITIONER |
Declaration of Kenneth A. Walters, Ph.D. in Support of Petitioner¿¿¿s Reply to Patent Owner¿¿¿s Response | Nov 1, 2017 | EXHIBIT | PETITIONER |
Antibacterial activity of topical antifungal agent in the infected sites- study- skin permeability and absorption to horny materials | Nov 1, 2017 | EXHIBIT | PETITIONER |
Final Printed Labeling for Center for Drug Evaluation and Research Application No. 21-022, Penlac¿¿¿ Nail Lacquer (Ciclopirox) Topical Solution, 8% | Nov 1, 2017 | EXHIBIT | PETITIONER |
Kaken Research & Development Division: R&D Pipeline | Nov 1, 2017 | EXHIBIT | PETITIONER |
Leaked Documents Shed Light on the Defunct Pharmacy that Brought Valeant to its Knees | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Under Criminal Investigation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO - Q3 2015 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant, Philidor RX, and the Uninformed Attack on Specialty Pharmacy | Nov 1, 2017 | EXHIBIT | PETITIONER |
U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies | Nov 1, 2017 | EXHIBIT | PETITIONER |
Adventures in Prior Authorization | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmacist at Center of Valeant Scandal Accuses Drugmaker of ¿¿¿Massive Fraud¿¿¿ | Nov 1, 2017 | EXHIBIT | PETITIONER |
Suit Alleges Valeant Ran Secret Prescription Refill Scam | Nov 1, 2017 | EXHIBIT | PETITIONER |
Is Walgreens Valeant¿¿¿s New Philidor | Nov 1, 2017 | EXHIBIT | PETITIONER |
The King¿¿¿s Gambit: Valeant¿¿¿s Big Secret | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant: Could this be the Pharmaceutical Enron | Nov 1, 2017 | EXHIBIT | PETITIONER |
Yahoo Finance, Valeant Pharmaceuticals International, Inc., Stock Price Historical Values (Daily), dated from October 1, 2015 through December 31, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Declaration of Jeffrey M. Weinberg, M.D. in Support of Petitioner¿¿¿s Reply to Patent Owner¿¿¿s Response | Nov 1, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 1, 2017 | EXHIBIT | PETITIONER |
PUBLIC VERSION Declaration of John C. Staines, Jr. in Support of Petitioner¿¿¿s Reply to Patent Owner¿¿¿s Response | Nov 1, 2017 | EXHIBIT | PETITIONER |
Dermatologic conditions of the foot | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmacokinetics of antimycotics with emphasis on local treatment | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Kerydin¿¿ (tavaborole) topical solution, 5%, Anacor Pharmaceuticals, Inc. | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Diflucan¿¿ (fluconazole) tablets, Pfizer Inc., NDA 19-949 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Sporanox¿¿ (itraconazole) capsules, Janssen Pharmaceutical Company, NDA 20-083 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Lamisil¿¿ (terbinafine) DermGel¿¿¿, 1% Gel, Jock Itch Product 6g Tube. Novartis Consumer Health, Inc., NDA 21-958 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Terbinafine Hydrochloride Cream, 1% | Nov 1, 2017 | EXHIBIT | PETITIONER |
Antifungal drugs for onychomycosis: efficacy, safety, and mechanisms of action | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmacy¿¿¿s Sales Tactics Disclosed | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., Investor Conference Call Presentation, October 26, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant and Pharmacy More Intertwined than Thought | Nov 1, 2017 | EXHIBIT | PETITIONER |
Drug Makers Sidestep Barriers on Pricing | Nov 1, 2017 | EXHIBIT | PETITIONER |
Beyond Valeant, U.S. Payers Scrutinize Other Drugmaker Ties to Pharmacies,¿¿¿ D. Beasley, Reuters, Health News, October 30, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Plunges on Report U.S. Attorney Pursuing Criminal Charges against the Company | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive | Nov 1, 2017 | EXHIBIT | PETITIONER |
Prior Authorization,¿¿¿ The Academy of Managed Care Pharmacy¿¿¿s Concepts in Managed Care Pharmacy | Nov 1, 2017 | EXHIBIT | PETITIONER |
Curing the Prior Authorization Headache | Nov 1, 2017 | EXHIBIT | PETITIONER |
The Valeant Executive Who Could¿¿¿ve Saved Bill Ackman¿¿¿s Investment Just Walked Out the Door | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Shares Fall After Sales and Earnings Targets Cut | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Slumps Again After Rebutting Critical Report | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals Under Investigation by Federal Prosecutors | Nov 1, 2017 | EXHIBIT | PETITIONER |
The Fraud Allegations Against Valeant Exposed an Industry Secret that¿¿¿s going to Infuriate Washington | Nov 1, 2017 | EXHIBIT | PETITIONER |
CVS, Express Scripts, UnitedHealth Group Cut Off Philidor, Pharmacy Used by Valeant | Nov 1, 2017 | EXHIBIT | PETITIONER |
Label for Lamisil¿¿ (terbinafine) tablets, Novartis Pharmaceuticals Corporation, NDA 20-539 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant to Terminate Relationship with Philidor | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update | Nov 1, 2017 | EXHIBIT | PETITIONER |
Mike Pearson is on His Way Out of Valeant, Former CFO Refuses to Leave Board | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Ex-CEO, Ex-CFO Are a Focus of U.S. Criminal Probe | Nov 1, 2017 | EXHIBIT | PETITIONER |
Two are Charged in Fraud and Kickback Scheme Against Valeant Pharmaceuticals | Nov 1, 2017 | EXHIBIT | PETITIONER |
A Realistic Approach to the Obviousness of Inventions | Nov 1, 2017 | EXHIBIT | PETITIONER |
The Pharmaceutical Industry ¿¿¿ Prices and Progress | Nov 1, 2017 | EXHIBIT | PETITIONER |
How Increased Competition From Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry: a CBO Study | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmaceutical Industry Antitrust Handbook | Nov 1, 2017 | EXHIBIT | PETITIONER |
Health Insurance and the Growth in Pharmaceutical Expenditures | Nov 1, 2017 | EXHIBIT | PETITIONER |
100 Best-Selling, Most Prescribed Branded Drugs through March | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Under Investigation by SEC | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Sold Some Drugs Twice | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO - Q3 2016 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. 1Q 2017 Financial Results Conference Call Presentation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q4 2015 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., Jefferies Autumn 2015 Global Healthcare Conference | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q2 2016 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q1 2017 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Brief, VRX.TO ¿¿¿ Q2 2017 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended March 31, 2017 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-Q, for the Quarterly Period Ended June 30, 2017 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Product Differentiation, Market Structure, and Competition | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Presentation, dated February 23, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Emmy Co-Host Mario Lopez Spotlights Valeant¿¿¿s Jublia on the Red Carpet | Nov 1, 2017 | EXHIBIT | PETITIONER |
The life cycle of a pharmaceutical brand | Nov 1, 2017 | EXHIBIT | PETITIONER |
Prescription Drug Pricing in the Private Sector: a CBO Paper | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Q2 2015 Financial Results Presentation, dated July 23, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. First Quarter 2016 Conference Call Presentation, dated June 7, 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year 2015 Supplemental Information Presentation, dated April 29, 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. 2Q 17 Financial Results Presentation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant: An Enduring Engine for Growth | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Script Tracker | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Second Quarter 2016 Conference Call Presentation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Inside the Secret World of Drug Company Rebates | Nov 1, 2017 | EXHIBIT | PETITIONER |
Here¿¿¿s How Drug Prices Actually Work | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q1 2016 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q4 2016 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Q3 2015 Financial Results Presentation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Second Quarter 2014 Financial Results Conference Call Presentation, dated July 31, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharmaceutical Super Bowl Ads Fall Flat | Nov 1, 2017 | EXHIBIT | PETITIONER |
A Healthy Ad Market | Nov 1, 2017 | EXHIBIT | PETITIONER |
Promotional spending for prescription drugs | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals (VRX) Q3 2014 Results Earnings Call Transcript | Nov 1, 2017 | EXHIBIT | PETITIONER |
Dow Pharmaceutical Sciences Becomes Wholly Owned Subsidiary as Acquisition by Valeant Pharmaceuticals International is Completed | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. (VRX) Q4 2014 Results Earnings Call Transcript, dated February 23, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Sandoz Press Release, ¿¿¿Sandoz Launches KerydinTM (Tavaborole) Topical Solution, 5% from Anacor Pharmaceuticals, Inc.,¿¿¿ dated September 22, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Secondary Considerations of Nonobviousness Analysis: The Use of Objective Indicia Following KSR v. Teleflex, 86 N.Y.U. L. Rev. 2070 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Hold the Valeant Applause | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pharma is the 7th Largest Ad Category in the U.S. at $6.4 billion Last Year | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. 2015 Financial Guidance Conference Call Presentation, dated January 8, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Fourth Quarter Preliminary Unaudited Financial Results 2015 Conference Call Presentation, dated March 15, 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Returns on Research and Development for 1990s New Drug Introductions | Nov 1, 2017 | EXHIBIT | PETITIONER |
New Drug Application 203567, Approval Letter from Julie Beitz, MD, Director, Office of Drug Evaluation III, Center for Drug Evaluation and Research to Sean Humphrey, Manager, Regulatory Affairs, Dow Pharmaceutical Sciences, Inc., dated June 6, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2013 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2012 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., 2015 J.P. Morgan Healthcare Conference, dated January 13, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Anacor Pharmaceuticals, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Bladders, Guts and Feet: The Psychology Behind Anthropomorphic Body Parts | Nov 1, 2017 | EXHIBIT | PETITIONER |
A Financial Perspective on the Topical Treatment of Onychomycosis | Nov 1, 2017 | EXHIBIT | PETITIONER |
CVS Just Made Valeant¿¿¿s Day Even Worse | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Brand-Name Drugs by Retail Sales in 2001 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Brand-Name Drugs by Retail Sales in 2002 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. First Quarter 2015 Financial Results Conference Call Presentation | Nov 1, 2017 | EXHIBIT | PETITIONER |
Anacor Pharmaceuticals Reports Third Quarter 2015 Financial Results | Nov 1, 2017 | EXHIBIT | PETITIONER |
Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising | Nov 1, 2017 | EXHIBIT | PETITIONER |
Direct to Consumer Advertising and Prescription Choice | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. Third Quarter 2014 Financial Results Conference Call Presentation, dated October 20, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Physicians-Pharmaceutical Sales Representatives interactions and Conflict of Interest: Challenges and Solutions | Nov 1, 2017 | EXHIBIT | PETITIONER |
Following the Script: How Drug Reps Make Friends and Influence Doctors | Nov 1, 2017 | EXHIBIT | PETITIONER |
The Drug Pushers | Nov 1, 2017 | EXHIBIT | PETITIONER |
Promotion and Market Share in the Proton Pump Inhibitor Market: A Case Study | Nov 1, 2017 | EXHIBIT | PETITIONER |
An Exploratory Study to Improve Sales Operations When Selling Multiple Prescription Drugs | Nov 1, 2017 | EXHIBIT | PETITIONER |
Physician Awareness of Drug Cost: A Systematic Review | Nov 1, 2017 | EXHIBIT | PETITIONER |
Physicians¿¿¿ Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most? | Nov 1, 2017 | EXHIBIT | PETITIONER |
Copay Programs¿¿¿ Increased Value to Manufacturers is Matched by Rising Criticism,¿¿¿ S. Shelly, Pharmaceutical Commerce, January 15, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
CVS Plans to Restrict $1,000 Toenail Fungus Drug Jublia | Nov 1, 2017 | EXHIBIT | PETITIONER |
Unbelievable¿¿¿Toe Nail Fungus?...Seriously?¿¿¿ B. Schenk, Pharmacy Benefit News, June 23, 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc., U.S. Securities and Exchange Commission Form 10-K, for the Fiscal Year Ended December 31, 2014 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Ortho Dermatologics RX Access Program | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant, Woes Rising, Backs Away From Boldness to Calm Investors | Nov 1, 2017 | EXHIBIT | PETITIONER |
With Valeant, Things Can Always be Worse, and the Past is Never Buried | Nov 1, 2017 | EXHIBIT | PETITIONER |
Pricing and reimbursement in U.S. pharmaceutical markets | Nov 1, 2017 | EXHIBIT | PETITIONER |
Dollar Yen Exchange Rate (USD JPY) ¿¿¿ Historical Chart ¿¿¿ MacroTrends | Nov 1, 2017 | EXHIBIT | PETITIONER |
Prescription drug expenditures in 2000: The upward trend continues | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Brand-Name Drugs by Retail Sales in 2000 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Brand-Name Drugs by Retail Sales in 2003 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Drugs for 2004 by Sales | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Drugs for 2005 by Sales | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Drugs for 2006 by Sales | Nov 1, 2017 | EXHIBIT | PETITIONER |
Top 200 Drugs for 2007 by Sales | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements for the 3Q of Fiscal 2016 | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Ciclopirox | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Tavaborole, | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Terbinafine | Nov 1, 2017 | EXHIBIT | PETITIONER |
Valeant Pharmaceuticals International, Inc. (VRX) Q2 2014 Results Earnings Call Transcript, dated July 31, 2014, | Nov 1, 2017 | EXHIBIT | PETITIONER |
Kaken Exhibit 2115, Certificate of Translation for the Evidentiary Declaration of Motonori Miyakawa | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2015 | Nov 1, 2017 | EXHIBIT | PETITIONER |
onsolidated Financial Results for Fiscal 2015 (Reference Data of Financial Statements for the 3Q of Fiscal 2015) | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements Fiscal 2016 1st Quarter) | Nov 1, 2017 | EXHIBIT | PETITIONER |
Consolidated Financial Results for Fiscal 2016 (Reference Data of Financial Statements for the 2Q of Fiscal 2016), | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Efinaconazole | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Fluconazole | Nov 1, 2017 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Search results for Itraconazole | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q1 2015 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Thomas Reuters StreetEvents, Edited Transcript, VRX.TO ¿¿¿ Q2 2015 Valeant Pharmaceuticals International Inc. Earnings Call | Nov 1, 2017 | EXHIBIT | PETITIONER |
Kaken Exhibit 2100, Evidentiary Declaration of Edward Shupenus | Nov 1, 2017 | EXHIBIT | PETITIONER |
Kaken Exhibit 2106, Evidentiary Declaration of Vincent A. Thomas, CPA, CVA, CFF, ABV | Nov 1, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 1, 2017 | EXHIBIT | PETITIONER |
Kaken Exhibit 2114, Evidentiary Declaration of Motonori Miyakawa | Nov 1, 2017 | EXHIBIT | PETITIONER |
PETITIONERS UPDATED EXHIBIT LIST | Nov 1, 2017 | PAPER | PETITIONER |
Patent Owners Motion for Pro Hac Vice Admission of Barbara R. Rudolph, Ph.D., and Petitioners Motion for Pro Hac Vice Admission of Lisa N. Phillips 37 C.F.R. sec 42.10 | Sep 27, 2017 | PAPER | BOARD |
Notice of Deposition of B. E. Elewski | Sep 27, 2017 | PAPER | PETITIONER |
NOTICE OF DEPOSITION OF YOSHIYUKI TATSUMI, PH.D | Sep 26, 2017 | PAPER | PETITIONER |
NOTICE OF DEPOSITION OF VINCENT A THOMAS | Sep 26, 2017 | PAPER | PETITIONER |
Order - Stay of Reissue Application No. 15/405,171 | Aug 31, 2017 | PAPER | BOARD |
Petitioners' Unopposed Motion For Hac Vice Admission of Lisa N. Phillips | Aug 23, 2017 | PAPER | PETITIONER |
Declaration of Lisa N. Phillips | Aug 23, 2017 | PAPER | PETITIONER |
PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED WITH PATENT OWNER¿¿¿S RESPONSE PURSUANT TO 37 C.F.R. ¿¿ 42.64(b)(1) | Aug 8, 2017 | PAPER | PETITIONER |
Kaken Exhibit 2027 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2092 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Patent Owners' Motion to Seal Exhibits 2093-2095, 2098, and 2099 | Aug 1, 2017 | PAPER | PATENT OWNER |
Kaken Exhibit 2024 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2025 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2026 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2028 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2029 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2030 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2031 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2032 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2033 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2034 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2035 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2036 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2037 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2038 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2039 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2040 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2041 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2042 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2043 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2044 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2045 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2046 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2047 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2048 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2049 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2050 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2051 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2052 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2053 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2054 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2055 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2056 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2057 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2058 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2059 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2060 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2062 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2063 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2064 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2065 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2066 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2067 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2068 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2069 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2070 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2071 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2072 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2073 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2074 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2075 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2076 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2077 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2078 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2079 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2080 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2081 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2082 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2083 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2084 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2085 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2086 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2087 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2088 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2089 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2090 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2091 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2096 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2097 | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Aug 1, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Aug 1, 2017 | PAPER | PATENT OWNER |
Patent Owner's Response | Aug 1, 2017 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Jul 18, 2017 | PAPER | PATENT OWNER |
Kaken Exhibit 2023 | Jul 18, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Unopposed Motion For Pro Hac Vice Admission of Barbara R. Rudolph, Ph.D. | Jul 18, 2017 | PAPER | PATENT OWNER |
PETITIONERS¿¿¿ REPLY TO PATENT OWNERS¿¿¿ OPPOSITION TO PETITIONERS¿¿¿ MOTION TO STAY REISSUE PROCEEDING | Jul 8, 2017 | PAPER | PETITIONER |
Patent Owner's Opposition to Petitioner's Motion to Stay Reissue Proceeding | Jul 3, 2017 | PAPER | PATENT OWNER |
Notice of Deposition of Kenneth A. Walters, Ph.D. | Jun 29, 2017 | PAPER | PATENT OWNER |
Patent Owner's Fourth Updated Mandatory Notices | Jun 23, 2017 | PAPER | PATENT OWNER |
Petitioners' Motion to Stay Related Reissue Proceedings | Jun 23, 2017 | PAPER | PETITIONER |
Reissue Application No. 15/405,171, Preliminary
Amendment and Remarks, dated 1/12/2017 | Jun 23, 2017 | EXHIBIT | PETITIONER |
Petitioner's Submission of Transcript of June 13, 2017 Conference Call | Jun 16, 2017 | PAPER | PETITIONER |
ORDER Conduct of the Proceeding | Jun 14, 2017 | PAPER | BOARD |
PETITIONERS¿¿¿ OBJECTIONS TO EVIDENCE SUBMITTED WITH PATENT OWNER¿¿¿S PRELIMINARY RESPONSE PURSUANT TO 37 C.F.R. ¿¿ 42.64(b)(1) | May 15, 2017 | PAPER | PETITIONER |
Patent Owner's Objections to Evidence | May 15, 2017 | PAPER | PATENT OWNER |
DECISION - Institution of Inter Partes Review | May 1, 2017 | PAPER | BOARD |
SCHEDULING ORDER | May 1, 2017 | PAPER | BOARD |
Conduct of the Proceeding | Mar 1, 2017 | PAPER | BOARD |
Patent Owner's Updated Mandatory Notices | Feb 24, 2017 | PAPER | PATENT OWNER |
Petitioners Submission of Transcript of February 21, 2017 Conference Call | Feb 24, 2017 | PAPER | PETITIONER |
Kaken Exhibit 2004 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2006 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2007 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2009 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2010 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2011 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2013 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2014 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Mandatory Notices | Feb 2, 2017 | PAPER | PATENT OWNER |
Patent Owner's Preliminary Response | Feb 2, 2017 | PAPER | PATENT OWNER |
Kaken Exhibit 2001 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2002 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2003 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2005 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2008 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2012 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2015 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2016 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2017 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2018 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2019 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2020 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2021 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Kaken Exhibit 2022 | Feb 2, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Mandatory Notices | Dec 27, 2016 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Dec 12, 2016 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Dec 12, 2016 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Nov 16, 2016 | PAPER | BOARD |
PETITION to Institute an Inter Partes Review of U.S. Patent No. 7,214,506 | Nov 2, 2016 | PAPER | PETITIONER |
U.S. Pat. No. 7,214,506 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Certified English Translation of Japanese Pat. App. No. 11/214369 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Orange Book Excerpt for Valeant¿¿¿s Jublia | Nov 2, 2016 | EXHIBIT | PETITIONER |
U.S. Pat. No. 5,620,994 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Power of Attorney | Nov 2, 2016 | PAPER | PETITIONER |
Press Release | Nov 2, 2016 | EXHIBIT | PETITIONER |
Declaration of Kenneth Walters | Nov 2, 2016 | EXHIBIT | PETITIONER |
Prosecution History of U.S. Pat. No. 7,214,506 | Nov 2, 2016 | EXHIBIT | PETITIONER |
U.S. Pat. No. 5,716,969 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Certified English Translation of Japanese Pat. App. Pub. No. 10- 226639 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Ogura, H. et al., Chem. Pharm. Bull, 47(10) 1417-1425 (1999) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Comparison between the Priority Document | Nov 2, 2016 | EXHIBIT | PETITIONER |
Publication of PCT/JP00/04617 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Hay, R.J., et al., Clinical and Experimental Dermatology, 10:111-115 (1985) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Kaken Abstracts | Nov 2, 2016 | EXHIBIT | PETITIONER |
Ceschin-Roques C.G., et al., Skin Pharmacol, 4: 89-94 (1991) | Nov 2, 2016 | EXHIBIT | PETITIONER |
van Hoogdalem, E.J. et al., Eur J Pharm Sci 5: 119-127 (1997) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Quintanar- Guerrero, D. et al., Drug Dev Ind Pharm, 24: 685-690 (1998) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Mertin, D., Journal of Pharmacy and Pharmacology, 49(1): 30-34 (1997) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Niewerth, M., Drugs 58(2):283-296 (1999) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Burch, G.E., Arch Derm Syphilol 53: 39-41 (1946) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Baden H.P., et al., Biochim Biophys Acta 322:269¿¿¿278 (1973) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Hay, R.J., Journal of Antimicrobial Chemotherapy 20: 1-5 (1987) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Aly, R., J. Am. Acad. Dermatol., 31:S21¿¿¿S25 (1994) | Nov 2, 2016 | EXHIBIT | PETITIONER |
J. of the American Academy of Dermatology, 40 (Suppl):S21¿¿¿6 (1999) | Nov 2, 2016 | EXHIBIT | PETITIONER |
J. of the American Academy of Dermatology, 35:3(2): S26-S30 (1996) | Nov 2, 2016 | EXHIBIT | PETITIONER |
U.S. Pat. No. 5,391,367 | Nov 2, 2016 | EXHIBIT | PETITIONER |
Stuttgen, G. and Bauer, E., Mycoses, 25(2): 74-80 (1992) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Franz, T.J., Dermatol, 184(Suppl 1): 18-20 (1992) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Mertin, D., Journal of Pharmacy and Pharmacology, 49(3): 241-245 (1997) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Mertin, D., Journal of Pharmacy and Pharmacology, 49(9): 866-872 (1997) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Kobayashi Y. et al., Chem Pharm Bull 46: 1797- 1802 (1998) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Heine, C. AdWeek. (Jan. 27, 2015) | Nov 2, 2016 | EXHIBIT | PETITIONER |
J. of the European Academy of Dermatology and Venereology 4 (Supp. 1)(1995) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Summerbell, R.C., Dermatology, 194 (Supp. 1): 32-36 (1997) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Vanderdonckt, J., et al., Mykosen, 19(7):251-256 (1975) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Buck, D.S. et al., The Journal of Family Practice, 38(6): 601-605 (1994) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Spruit, D., J Invest Dermatol, 56(5): 359-361 (1971) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Walters, K.A., J Pharm Pharmacol 35: 28-33 (1983) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Walters, K.A., J Pharm Pharmacol, 37: 771-775 (1985) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Haria, M. and Bryson, H.M., Drugs, 49(1): 103-120 (1995) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Walters, K.A., J Invest Dermatol, 76: 76-79 (1981) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Walters, K.A., J Pharm Pharmacol, 37: 498-499 (1985) | Nov 2, 2016 | EXHIBIT | PETITIONER |
Declaration of Jeff Karr | Nov 2, 2016 | EXHIBIT | PETITIONER |
Jublia Package Insert | Nov 2, 2016 | EXHIBIT | PETITIONER |
Acrux DDS Pty Ltd. Corporate Website | Nov 2, 2016 | EXHIBIT | PETITIONER |
Acrux DDS Pty Ltd. Corporate Website | Nov 2, 2016 | EXHIBIT | PETITIONER |